Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
Iketani, S., Forouhar, F., Liu, H., Hong, S.J., Lin, F.Y., Nair, M.S., Zask, A., Huang, Y., Xing, L., Stockwell, B.R., Chavez, A., Ho, D.D.(2021) Nat Commun 12: 2016-2016
- PubMed: 33795671 
- DOI: https://doi.org/10.1038/s41467-021-22362-2
- Primary Citation of Related Structures:  
7JST, 7JSU, 7JT0, 7JT7, 7JW8 - PubMed Abstract: 
We report the identification of three structurally diverse compounds - compound 4, GC376, and MAC-5576 - as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors.
Organizational Affiliation: 
Aaron Diamond AIDS Research Center, Columbia University Irving Medical Center, New York, NY, USA.